company background image
ARAV

Aravive NasdaqGS:ARAV Stock Report

Last Price

US$1.79

Market Cap

US$107.1m

7D

1.7%

1Y

-17.1%

Updated

30 Jan, 2023

Data

Company Financials +

ARAV Stock Overview

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States.

ARAV fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Aravive, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Aravive
Historical stock prices
Current Share PriceUS$1.79
52 Week HighUS$2.40
52 Week LowUS$0.58
Beta2.37
1 Month Change35.61%
3 Month Change4.68%
1 Year Change-17.13%
3 Year Change-81.39%
5 Year Change-83.65%
Change since IPO-99.05%

Recent News & Updates

Recent updates

Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

Sep 03
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely

We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

May 15
We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Nov 06
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Jun 25
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Mar 18
Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?

Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Feb 09
Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth

Shareholder Returns

ARAVUS BiotechsUS Market
7D1.7%0.8%2.8%
1Y-17.1%7.1%-9.2%

Return vs Industry: ARAV underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: ARAV underperformed the US Market which returned -9.2% over the past year.

Price Volatility

Is ARAV's price volatile compared to industry and market?
ARAV volatility
ARAV Average Weekly Movement19.0%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: ARAV is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 19% a week.

Volatility Over Time: ARAV's weekly volatility has increased from 13% to 19% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200823Gail McIntyrehttps://aravive.com

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway.

Aravive, Inc. Fundamentals Summary

How do Aravive's earnings and revenue compare to its market cap?
ARAV fundamental statistics
Market CapUS$107.09m
Earnings (TTM)-US$60.15m
Revenue (TTM)US$8.65m

12.4x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ARAV income statement (TTM)
RevenueUS$8.65m
Cost of RevenueUS$61.18m
Gross Profit-US$52.53m
Other ExpensesUS$7.62m
Earnings-US$60.15m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.01
Gross Margin-607.44%
Net Profit Margin-695.57%
Debt/Equity Ratio0%

How did ARAV perform over the long term?

See historical performance and comparison